(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY(PCT)
`
`(19) World Intellectual Property Organization
`International Bureau
`
`(43) International Publication Date
`18 October 2001 (18.10.2001)
`
`
`
`PCT
`
`(10) International Publication Number
`WO 01/77073 Al
`
`(51)
`
`CO07D 207/08,
`International Patent Classification’:
`207/09, 207/12, 207/14, 209/62, 407/04, A61K 31/40,
`31/435
`
`(21)
`
`International Application Number:
`
`PCT/US01/11001
`
`16711 Trans-Canada Highway, Kirkland, Québec H9H
`3L1 (CA). RYDZEWSKI,Robert [US/US]; 180 Kimball
`Way, South San Francisco, CA 94080 (US). OKAMOTO,
`Osamu [JP/JP]; 2-3, Nihombashi Honcho 2-chome,
`Chuo-ku, Tokyo 103-8416 (JP).
`
`(22)
`
`International Filing Date:
`
`4 April 2001 (04.04.2001)
`
`(74)
`
`Agent: WALLINGER,Nicole, M.; Merck & Co., Inc.,
`126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
`
`(25)
`
`Filing Language:
`
`(26)
`
`Publication Language:
`
`English
`
`English
`
`(31)
`
`(30)
`
`Priority Data:
`60/195,557
`
`6 April 2000 (06.04.2000)
`
`US
`
`(71)
`
`except US):
`(for all designated States
`Applicants
`MERCK FROSST CANADA & CO. [CA/CA]; 16711
`Trans-Canada Highway, Kirkland, Québec H9H 3L1
`(CA). AXYS PHARMACEUTICALS, INC. [US/US];
`180 Kimball Way, South San Francisco, CA 94080 (US).
`BANYU PHARMACEUTICALCoO., LTD. [JP/JP]; 2-3,
`Nihombashi Honcho 2-chome, Chuo-ku, Tokyo 103-8416
`(JP).
`
`(72)
`(75)
`
`Inventors; and
`Inventors/Applicants (for US only): PRASIT, Petpi-
`boon [CA/CA]; 16711 Trans-Canada Highway, Kirkland,
`Québec H9H 3L1 (CA). FALGUEYRET, Jean-Pierre
`[CA/CA];
`16711 Trans-Canada Highway, Kirkland,
`Québec H9H 3L1 (CA). OBALLA, Renata [CA/CA];
`
`Designated States (national): AE, AG, AL, AM, AT, AU,
`AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
`CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
`HR, HU,ID,IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,
`LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
`NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
`TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
`
`(84)
`
`Designated States (regional): ARIPO patent (GH, GM,
`KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
`patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
`patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,IE,
`TT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
`CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
`
`Published:
`
`with international search report
`
`For two-letter codes and other abbreviations, refer to the "Guid-
`ance Notes on Codes andAbbreviations" appearing at the begin-
`ning ofeach regular issue ofthe PCT Gazette.
`
`WO01/77073A1
`
`(54) Title: CATHEPSIN CYSTEINE PROTEASE INHIBITORS
`
`(57) Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited
`to, inhibitors of Cathepsins K and L. These compoundsare useful for treating diseases in which inhibition of bone resorption is
`indicated, such as osteoporosis.
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`TITLE OF THE INVENTION
`CATHEPSIN CYSTEINE PROTEASE INHIBITORS
`
`10
`
`BACKGROUND OF THE INVENTION
`A variety of disorders in humans and other mammals involve or are
`associated with abnormal bone resorption. Such disorders include, but are not limited
`to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally
`increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid
`arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic
`bone disease, hypercalcemia of malignancy, and multiple myeloma. One of the most
`common ofthese disorders is osteoporosis, which in its most frequent manifestation
`occurs in postmenopausal women. Osteoporosis is a systemic skeletal disease
`characterized by a low bone mass and microarchitectural deterioration of bone tissue,
`with a consequent increasein bone fragility and susceptibility to fracture.
`Osteoporotic fractures are a major cause of morbidity and mortality in the elderly
`15
`population. As many as 50% of womenandathird of men will experience an
`osteoporotic fracture. A large segmentof the older population already has low bone
`density and a high risk of fractures. There is a significant need to both prevent and
`treat osteoporosis and other conditions associated with bone resorption. Because
`osteoporosis, as well as other disorders associated with bone loss, are generally
`chronic conditions, it is believed that appropriate therapy will typically require
`
`20
`
`chronic treatment.
`Osteoporosis is characterized by progressive loss of bone architecture
`and mineralization leading to the loss in bone strength and an increasedfracture rate.
`The skeleton is constantly being remodeled by a balance between osteoblasts that lay
`down new boneand osteoclasts that breakdown, or resorb, bone. In some disease
`conditions and advancing age the balance between bone formation and resorption is
`disrupted; bone is removedat a faster rate. Such a prolonged imbalance of resorption
`over formation leads to weaker bone structure and a higher riskof fractures.
`Boneresorption is primarily performed by osteoclasts, which are
`multinuclear giant cells. Osteoclasts resorb bone by forming an initial cellular
`attachmentto bonetissue, followed by the formation of an extracellular compartment
`or lacunae. The lacunae are maintained at a low pH by a proton-ATP pump. The
`acidified environmentin the lacunae allowsfor initial demineralization of bone
`followed by the degradation of boneproteins or collagen by proteases such as cysteine
`
`25
`
`30
`
`35
`
`-l-
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`proteases. See Delaisse, J. M. et al., 1980, Biochem J 192:365-368; Delaisse, J. et al.,
`1984, Biochem Biophys Res Commun :441-447; Delaisse, J. M. et al.,1987, Bone
`8:305-313, which are hereby incorporated by reference in their entirety. Collagen
`constitutes 95 % of the organic matrix of bone. Therefore, proteases involved in
`collagen degradation are an essential component of bone turnover, and as a
`consequence, the development and progression of osteoporosis.
`Cathepsins belong to the papain superfamily of cysteine proteases.
`These proteases function in the normal physiological as well as pathological
`degradation of connective tissue. Cathepsins play a major role in intracellular protein
`degradation and turnover and remodeling. To date, a number of cathepsin have been
`identified and sequenced from a number of sources. These cathepsins are naturally
`found in a wide variety of tissues. For example, cathepsin B, F, H, L, K, S, W, and Z
`have been cloned. Cathepsin K (which is also known bythe abbreviation cat Ks)
`is
`also knownas cathepsin O and cathepsin O2. See PCT Application WO 96/13523,
`Khepri Pharmaceuticals, Inc., published May 9, 1996, whichis hereby incorporated by
`reference in its entirety. Cathepsin L is implicated in normal lysosomalproteolysisas
`well as several disease states, including, but not limited to, metastasis of melanomas.
`Cathepsin S is implicated in Alzheimer’s disease and certain autoimmune disorders,
`including, but not limited to juvenile onset diabetes, multiple sclerosis, pemphigus
`vulgaris, Graves’ disease, myasthenia gravis, systemic lupus erythemotasus,
`rheumatoid arthritis and Hashimoto’s thyroiditis; allergic disorders, including, but not
`limited to asthma; and allogenic immunberesponses,including, but not limited to,
`rejection of organ transplants ortissue grafts.
`Cysteine protease inhibitors such as E-64 (trans-epoxysuccinyl-L-
`leucylamide-(4-guanidino) butane) are known to beeffective in inhibiting bone
`resorption. See Delaisse, J. M. et al., 1987, Bone 8:305-313, which is hereby
`incorporated by reference in its entirety. Recently, cathepsin K was cloned and found
`specifically expressedin osteoclasts See Tezuka, K.etal., 1994, J Biol Chem
`269:1106-1109; Shi, G. P. et al.,1995, FEBS Lett 357:129-134; Bromme, D. and
`Okamoto, K., 1995, Biol Chem Hoppe Seyler 376:379-384;, Bromme, D.et al., 1996,
`J Biol Chem 271:2126-2132; Drake, F. H. et al., 1996, J Biol Chem 271:12511-
`12516, which are hereby incorporated byreference in their entirety. Concurrentto the
`cloning,the autosomalrecessive disorder, pycnodysostosis, characterized by an
`osteopetrotic phenotype with a decrease in bone resorption, was mapped to mutations
`presentin the cathepsin K gene. Todate, all mutations identified in the cathepsin K
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`-2 -
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`gene are knownto result in inactive protein. See Gelb, B. D. et al., 1996, Science
`273:1236-1238; Johnson, M.R.et al., 1996, Genome Res 6:1050-1055, which are
`hereby incorporated by reference in their entirety. Therefore, it appears that cathepsin
`K is involved in osteoclast mediated bone resorption.
`Cathepsin K is synthesized as a 37 kDa pre-pro enzyme, which is
`localized to the lysosomal compartment and whereit is presumably autoactivated to
`the mature 27 kDa enzymeat low pH. See McQueney, M.S. e¢ al., 1997, J Biol
`Chem 272:13955-13960; Littlewood-Evans,A. et al., 1997, Bone 20:81-86, which are
`hereby incorporatedby reference in their entirety. Cathepsin K is most closely related
`to cathepsin S having 56 % sequence identity at the amino acid level. The S2P2
`substrate specificity of cathepsin K is similar to that of cathepsin S with a preference
`in the P1 and P2 positions for a positively charged residue such as arginine, and a
`hydrophobic residue such as phenylalanine or leucine, respectively. See Bromme, D.
`et al., 1996, J Biol Chem 271: 2126-2132; Bossard, M.J. et al.,1996, J Biol Chem
`271:12517-12524, which are hereby incorporated by reference in their entirety.
`Cathepsin K is active at a broad pH range with significant activity between pH 4-8,
`thus allowing for goodcatalytic activity in the resorption lacunae of osteoclasts where
`the pH is about 4-5.
`Humantype I collagen, the major collagen in bone is a good substrate
`for cathepsin K. See Kafienah, W., ef al., 1998, Biochem J 331:727-732, which is
`hereby incorporated by referencein its entirety. In vitro experiments using antisense
`-oligonucleotides to cathepsin K, have shown diminished boneresorption ivitro,
`which is probably due to a reduction in translation of cathepsin K mRNA.See Inui,
`T., et al., 1997, J Biol Chem 272:8109-8112, which is hereby incorporated by
`reference in its entirety. The crystal structure of cathepsin K has been resolved. See
`McGrath, M.E., et al., 1997, Nat Struct Biol 4:105-109; Zhao,B., et al., 1997, Nat
`Struct Biol 4: 109-11, which are hereby incorporated by referencein their entirety.
`Also,selective peptide based inhibitors of cathepsin K have been developed See
`Bromime, D., et al., 1996, Biochem J 315:85-89; Thompson,S. K., et al.,1997, Proc
`Natl Acad Sci U S A 94:14249-14254, which are hereby incorporated by reference in
`their entirety. Accordingly, inhibitors of Cathepsin K can reduce bone resorption.
`Such inhibitors would be useful in treating disorders involving boneresorption, such
`
`as osteoporosis.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`Compounds of the instant invention are useful as inhibitors of
`cathepsins. More particularly, the compoundsofthe instant invention are useful as
`inhibitors of Cathepsins K and L.
`It is therefore an object of the invention to provide compounds which
`inhibit cathepsin activity in a mammalin needthereof.
`It is another object of the invention to provide compounds whichare
`useful for treating and/or preventing boneloss in a mammal in needthereof.
`It is another object of the invention to provide compounds which are
`useful to reduce bone loss in a mammalin need thereof.
`It is another object of the invention to provide compounds whichare
`useful for treating and/or preventing bone fractures in a mammal in need thereof.
`It is another object of the invention to provide compounds which are
`useful for treating and/or preventing osteoporosis in a mammal in need thereof.
`It is another object of the invention to provide compounds which are
`useful for treating and/or preventing cathepsin dependent conditions or diseasestates
`in a mammalin need thereof.
`
`5
`
`10
`
`15
`
`SUMMARYOF THE INVENTION
`The present invention relates to compoundsof the following chemical
`
`20
`
`formula:
`
`wWfwa-Zz©wya”.
`
`Z=
`
`25
`
`30
`
`wherein R1 and R2are each independently selected from the group consisting of
`hydrogen,alkyl, oxo, -(CH2)p-NH-S(O)2-R3, -(CH2)p-NH-CO-R4,
`-C(O)2R6, -(CH2)pORS, -OR6, -(CH2)pNR7R8, -CN, -
`NH(CH2)pR3, -(CH2)pR3, -R3 , -C(O)NHR® and -C(O)NR§;
`or R1 and R2 can be joined together to form a system selected from the
`group consisting of aryl, cycloalkyl! and heterocycloalkyl;
`
`A
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`R3is selected from the group consisting ofaryl, arylalkyl, cycloalkyl, and
`heterocycloalkyl, wherein said aryl, arylalkyl and cycloalkyl] groups
`are either unsubstituted or substituted with 1, 2 or 3 halogen atoms;
`R4is selected from the group consisting ofaryl, cycloalkyl, heterocycloalkyl, biaryl,
`CH(R10)-NHC(O)2R3, ORS, (CH2)pR9, (CH2)p(R%q, wherein said
`aryl, cycloalkyl, heterocycloalkyl and biaryl, groups are either
`unsubstituted or substituted with 1, 2 or 3 halogen atoms;
`R5is selected from the group consisting of alkyl, alkenyl, alkynyl, and (CH2)pR9;
`R6is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, and
`CH(R10)-NHC(0O)2R3;
`R7 and R8 are each independently selected from the group consisting of hydrogen,
`alkyl, alkenyl, alkynyl, and —(CH2)pR3;
`or R7 and R8 are joined together to form a system selected from the
`group consisting of aryl and heterocycloalkyl;
`R9is selected from the group consisting of aryl, cycloalkyl and heterocycloalky];
`R10 is selected from the group consisting of the side chains of the naturally occurring
`amino acids or unnaturally occurring amino acids;
`each n is independently an integer from zero to four;
`each p is independently an integer from zero to six;
`each q is independently an integer from zero to four;
`and the pharmaceutically acceptable salts thereof.
`The present invention also relate to pharmaceutical compositions
`comprising the compounds of the present invention and a pharmaceutically acceptable
`carrier.
`
`The present invention also relates to methods for making the
`pharmaceutical compositions of the present invention.
`The present invention also relates to methods of inhibiting cathepsin
`activity and/or treating cathepsin dependent conditions in a mammal in need thereof
`comprising administering to the mammal the compounds and pharmaceutical
`compositions of the present invention.
`The present invention also relates to methodsoftreating, preventing
`and/or reducing bone loss in a mammal in need thereof comprising administering to
`the mammal the compounds and pharmaceutical compositions of the present
`invention.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`5.
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`The present invention also relates to methods of inhibiting treating
`and/or preventing osteoporosis in a mammal in need thereof comprising administering
`to the mammal the compounds and pharmaceutical compositions of the present
`invention.
`
`5
`
`The present invention also relates to methods of reducing boneloss in
`a mammal in need thereof comprising administering to the mammal the compounds
`and pharmaceutical compositions of the present invention.
`The present invention also relates to methodsoftreating and/or
`preventing bone fractures in a mammal in need thereof comprising administering to
`10=the mammal the compounds and pharmaceutical compositions of the present
`invention.
`
`15
`
`The present invention relates to the use of the compounds and
`pharmaceutical compositions of the present invention for the preparation of a
`medicament for treating or preventing boneloss in a mammalin need thereof.
`The present invention relates to pharmaceutical compositions useful
`for treating or preventing bone loss in a mammal comprising a pharmaceutically
`effective amount of compounds of the present invention in association with
`pharmaceutically acceptable carriers.
`
`20
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`The present invention relates to compoundsof the following chemical
`
`formula:
`
`J.
`
`DVL2NJ
`Z2=0-Z
`
`25_wherein R! and R2 are each independently selected from the group consisting of
`hydrogen, alkyl, oxo, -(CH2)p-NH-S(O)2-R3, -(CH2)p-NH-CO-R4,
`-C(O)2R46, -(CH2)pORS, -ORS, -(CH2)pNR7R8, -CN, -
`NH(CH2)pR3, -(CH2)pR3, -R3, -C(O)NHR® and -C(O)NR4;
`or R1 and R2 can be joined together to form a system selected from the
`group consisting of aryl, cycloalkyl and heterocycloalkyl;
`
`30
`
`6 -
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`R3 is selected from the group consisting ofaryl, arylalkyl, cycloalkyl, and
`heterocycloalkyl, wherein said aryl, arylalkyl and cycloalky] groups
`are either unsubstituted or substituted with 1, 2 or 3 halogen atoms;
`R4is selected from the group consisting of aryl, cycloalkyl, heterocycloalkyl, biaryl,
`CH(R10)-NHC(O)2R3, OR5, (CH2)pR9, (CH2)p(R)q, wherein said
`aryl, cycloalkyl, heterocycloalkyl and biaryl, groups are either
`unsubstituted or substituted with 1, 2 or 3 halogen atoms;
`R5is selected from the group consisting of alkyl, alkenyl, alkynyl, and (CH2)pR9;
`RO is selected from the group consisting of hydrogen,alkyl, alkenyl, alkynyl, and
`CH(R10)-NHC(O)oR3;
`R7 and R8 are each independently selected from the group consisting of hydrogen,
`alkyl, alkenyl, alkynyl, and —CH2)pR3;
`or R7 and R8are joined together to form a system selected from the
`group consisting of aryl and heterocycloalky]l;
`RY is selected from the group consisting of aryl, cycloalkyl and heterocycloalkyl;
`R10 is selected from the group consisting of the side chains of the naturally occurring
`amino acids or unnaturally occurring aminoacids;
`each n is independently an integer from zero to four;
`each p is independently an integer from zero to six;
`each q is independently an integer from zero to four;
`and the pharmaceutically acceptable salts thereof.
`In the compoundsofthe present invention, R1 and R2 are each
`-
`independently and preferably selected from the group consisting of: hydrogen,
`(CH2)p-NH-S(0)2-R3, -(CH2)p-NH-CO-R4, -C(O)2R®, -(CH2)pOR5,
`-OR®6,-CN,
`-N(CH2)pR3, -(CH2)pR3, and -C(O)NR®;or R1 and R2 can be joined together to
`form a system selected from the group consisting of aryl, cycloalkyl and
`heterocycloalkyl.
`In the compoundsof the present invention, each n is independently and
`preferably an integer from zero to two.
`In the compoundsof the present invention, R!0 is preferably selected
`from the group consisting of the side chains of leucine and isoleucine.
`In the compoundsof the present invention, each p is independently and
`preferably an integer from zero to four.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`-7 -
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`An embodimentof the invention is a methodof inhibiting cathepsin
`activity in a mammalin need thereof, comprising administering to the mammal a
`therapeutically effective amount of any of the compounds or any of the above
`pharmaceutical compositions described above.
`A class of the embodiment is the method wherein the cathepsin activity
`
`is cathepsin K activity.
`A secondclass of the embodiment is the method wherein the cathepsin
`
`activity is cathepsin L activity.
`Another embodiment of the invention is a method oftreating or
`preventing cathepsin dependentconditions in a mammal in need thereof, comprising
`administering to the mammala therapeutically effective amount of any of the
`compoundsor any of the above pharmaceutical compositions described above.
`A class of the embodimentis the method wherein the cathepsin activity
`
`is cathepsin K activity.
`A secondclass of the embodiment is the method wherein the cathepsin
`
`activity is cathepsin L activity.
`Another embodimentof the invention is a method oftreating or
`preventing boneloss in a mammalin needthereof, comprising administering to the
`mammala therapeutically effective amount of any of the compoundsor any of the
`above pharmaceutical compositions described above.
`Another embodimentof the invention is a method of reducing bone
`loss in a mammalin need thereof, comprising administering to the mammal a
`therapeutically effective amount of any ofthe compoundsor any of the above
`pharmaceutical compositions described above.
`Another embodiment of the invention is a method oftreating or
`preventing bonefractures in a mammal in need thereof, comprising administering to
`the mammal a therapeutically effective amount of any of the compoundsor any of the
`above pharmaceutical compositions described above.
`Another embodiment of the invention is a methodoftreating or
`preventing osteoporosis in a mammalin needthereof, comprising administering to the
`mammala therapeutically effective amount of any of the compoundsor any ofthe
`above pharmaceutical compositions described above.
`Exemplifying the invention is a pharmaceutical composition
`comprising any of the compounds described above and a pharmaceutically acceptable
`carrier. Also exemplifying the invention is a pharmaceutical composition made by
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`-8 -
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`combining any of the compounds described above and a pharmaceutically acceptable
`carrier. An illustration of the invention is a process for making a pharmaceutical
`composition comprising combining any of the compounds described above and a
`pharmaceutically acceptable carrier.
`Further exemplifying the invention is the use of any of the compounds
`described abovein the preparation of a medicamentfor the treatment and/or
`prevention of osteoporosis in a mammal in need thereof. Still further exemplifying
`the invention is the use of any of the compounds described abovein the preparation of
`a medicamentfor the treatment and/or prevention of: bone loss, bone resorption, bone
`fractures, and/or disorders related to cathepsin functioning.
`The present invention is also directed to combinations of any of the
`compoundsor any of the pharmaceutical compositions described above with one or
`more agents useful in the prevention or treatment of osteoporosis. For example, the
`compoundsofthe instant invention may be effectively administered in combination
`with effective amounts of other agents such as an organic bisphosphonate or an
`estrogen receptor modulator. Nonlimiting examples of said organic bisphosphonates
`include alendronate, clodronate, etidronate, ibandronate, incadronate, minodronate,
`neridronate, risedronate, piridronate, pamidronate, tiludronate, zoledronate,
`pharmaceutically acceptable salts or esters thereof, and mixtures thereof. Preferred
`organic bisphosphonates include alendronate and pharmaceutically acceptable salts
`and mixtures thereof. Most preferred is alendronate monosodium trihydrate.
`The precise dosage of the bisphosphonate will vary with the dosing
`schedule, the oral potency of the particular bisphosphonate chosen,the age, size, sex
`and condition of the mammal or human, the nature and severity of the disorder to be
`treated, and other relevant medical and physical factors. Thus, a precise
`pharmaceutically effective amount cannot be specified in advance and can be readily
`determined bythe caregiver or clinician. Appropriate amounts can be determined by
`routine experimentation from animal models and humanclinical studies. Generally,
`an appropriate amount of bisphosphonate is chosen to obtain a bone resorption
`inhibiting effect, i.e. a bone resorption inhibiting amountof the bisphosphonateis
`administered. For humans, an effective oral dose of bisphosphonateis typically from
`about 1.5 to about 6000 ug/kg body weight and preferably about 10 to about 2000
`pg/kg of body weight.
`For human oral compositions comprising alendronate,
`pharmaceutically acceptable salts thereof, or pharmaceutically acceptable derivatives
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`-9 -
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`thereof, a unit dosage typically comprises from about 8.75 mg to about 140 mg of the
`alendronate compound, on an alendronic acid active weightbasis, i.e. on the basis of
`the corresponding acid.
`For use in medicine, the salts of the compoundsof this invention refer
`to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful
`in the preparation of the compounds according to the invention or of their
`pharmaceutically acceptable salts. When the compoundsof the present invention
`contain a basic group, salts encompassed within the term "pharmaceutically
`acceptable salts" refer to non-toxic salts which are generally prepared by reacting the
`free base with a suitable organic or inorganic acid. Representative salts include the
`following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate,
`borate, bromide, calcium, camsylate, carbonate, chloride, clavulanate,citrate,
`dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate,
`glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide,
`hydrochloride, hydroxynaphthoate,iodide, isothionate, lactate, lactobionate, laurate,
`malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate,
`mucate, napsylate, nitrate, N-methylglucamine ammoniumsalt, oleate, oxalate,
`pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate,
`polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate,
`teoclate, tosylate, triethiodide and valerate. Furthermore, where the compoundsof the
`invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof
`may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal
`salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands,
`€.g., quaternary ammonium salts.
`The compoundsof the present invention can have chiral centers and
`occur as racemates, racemic mixtures, diastereomeric mixtures, and as individual
`
`diastereomers, or enantiomers with all isomeric forms being includedin the present
`invention. Therefore, where a compoundis chiral, the separate enantiomers,.
`substantially free of the other, are included within the scope of the invention; further
`includedare all mixtures of the two enantiomers. Also included within the scope of
`the invention are polymorphs, hydrates and solvates of the compoundsof the instant
`invention.
`
`The present invention includes within its scope prodrugsof the
`compoundsofthis invention. In general, such prodrugs will be functional derivatives
`of the compoundsofthis invention which are readily convertible in vivo into the
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`-10 -
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`required compound. Thus, in the methods of treatment of the present invention, the
`term "administering" shall encompassthe treatment of the various conditions
`described with the compound specifically disclosed or with a compound which may
`not be specifically disclosed, but which converts to the specified compound in vivo
`after administration to the patient. Conventional procedures for the selection and
`preparation of suitable prodrug derivatives are described, for example, in "Design of
`Prodrugs," ed. H. Bundgaard, Elsevier, 1985, which is incorporated by reference
`herein in its entirety. Metabolites of these compounds include active species
`produced upon introduction of compoundsof this invention into the biological milieu.
`The term "therapeutically effective amount" shall mean that amountof
`a drug or pharmaceutical agent that will elicit the biological or medical response of a
`tissue, system, animal or human that is being sought by a researcheror clinician.
`The term "bone resorption," as used herein, refers to the process by
`which osteoclasts degrade bone.
`The term "alkyl" shall mean straight or branched chain alkanes of one
`to ten total carbon atoms, or any number within this range G.e., methyl, ethyl, 1-
`propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
`The term "alkenyl" shall mean straight or branched chain alkenes of
`two to ten total carbon atoms, or any numberwithin this range containing at least one
`double bond(i.e., -CH=CHp, -CH»CH=CHb», -CH=CHCHs3, -CH»,CH=C(CHs3)y, etc.).
`
`The term "alkynyl" shall meanstraight or branched chain alkynes of
`two to ten total carbon atoms, or any numberwithin this range containing at least one
`triple bond(i.e., -C=CH, -CHy)C=H, -C=CCH3, -CH»)C=CCH>(CH3)p»,etc.).
`
`The term "cycloalkyl" shall mean cyclic rings of alkanes of three to
`eight total carbon atoms, or any number within this range (i.e., cyclopropyl,
`cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
`The term “cycloalkenyl” shall mean a substituting univalent group
`derived by conceptual removal of one hydrogen atom from an unsaturated monocyclic
`hydrocarbon containing a double bond(i.e., cyclopentenyl or cyclohexenyl).
`The term "cycloheteroalkyl," as used herein, shall mean a 3- to 8-
`membered fully saturated heterocyclic ring containing one or two heteroatoms chosen
`from N, O or S. Examples of cycloheteroalkyl groups include, but are not limited to,
`oxiranyl, piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, piperazinyl.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`-l1-
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`The term "aryl," as used herein, refers to a monocyclic or polycyclic
`system comprising at least one aromatic ring, wherein the monocylic or polycyclic
`system contains 0, 1, 2, 3, or 4 heteroatoms chosen from N, O, or S, and wherein the
`monocylic or polycylic system is either unsubstituted or substituted with one or more
`groups independently selected from hydrogen, halogen, C1-10 alkyl, C3-8 cycloalkyl,
`aryl, aryl Cj-g alkyl, amino, amino C1-8 alkyl, Cj-3 acylamino, C1-3 acylamino C1-8
`alkyl, C1-6 alkylamino, C1-6 alkylamino C1-8 alkyl, C1-6 dialkylamino, C1-6
`dialkylamino-C1-g alkyl, C1-4 alkoxy, C1-4 alkoxy C1-6 alkyl, hydroxycarbony],
`hydroxycarbonyl C1-6 alkyl, C1-5 alkoxycarbonyl, C1-3 alkoxycarbonyl C1-6 allxyl,
`hydroxycarbonyl C1-6 alkyloxy, hydroxy, hydroxy C1-6 alkyl, cyano,trifluoromethyl,
`oxo or C1-5 alkylcarbonyloxy. Examples of aryl include, but are not limited to,
`
`phenyl, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, imidazolyl, benzimidazolyl, indolyl,
`thienyl, furyl, dihydrobenzofuryl, benzo(1,3) dioxolane, oxazolyl, isoxazolyl and
`thiazolyl, which are either unsubstituted or substituted with one or more groups
`independently selected from hydrogen, halogen, C1-10 alkyl, C3-g cycloalkyl, aryl,
`aryl C1-8 alky!, amino, amino C1-8 alkyl, C1-3 acylamino, C1{-3 acylamino C1-g
`alkyl, C1-6 alkylamino, C1-6 alkylamino-C 1-8 alkyl, C1-6 dialkylamino, C16
`dialkylamino C1-8 alkyl, Cj-4 alkoxy, C1-4 alkoxy C1-6 alkyl, hydroxycarbony]l,
`hydroxycarbonyl C1-6 alkyl, C4-5 alkoxycarbonyl, C4-3 alkoxycarbonyl Cj-6 alkyl,
`hydroxycarbony] C1-6 alkyloxy, hydroxy, hydroxy C1-6 alkyl, cyano,trifluoromethyl,
`oxo or C1-5 alkylcarbonyloxy. Preferably, the aryl group is unsubstituted, mono-, di-,
`
`tri- or tetra-substituted with one to four of the above-named substituents; more
`preferably, the aryl group is unsubstituted, mono-, di- or tri-substituted with one to
`three of the above-namedsubstituents; most preferably, the ary! groupis
`unsubstituted, mono- or di-substituted with one to two of the above-named
`
`substituents.
`
`10
`
`15
`
`20
`
`25
`
`Wheneverthe term "alkyl" or "aryl" or either of their prefix roots
`appear in a name ofa substituent (e.g., aryl Co-g alkyl) it shall be interpreted as
`
`including those limitations given above for "alkyl" and "aryl." Designated numbers of
`carbon atoms(e.g., C1-10) shall refer independently to the numberof carbon atomsin
`
`30
`
`an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which
`alkyl appears as its prefix root.
`The terms "arylalkyl" and "alkylaryl" include an alkyl portion where
`alkyl is as defined above and to include an ary] portion where aryl is as defined above.
`Examples of arylalkyl include, but are not limited to, benzyl, fluorobenzyl,
`
`35
`
`-12-
`
`

`

`WO 01/77073
`
`PCT/US01/11001
`
`chlorobenzyl, phenylethyl, phenylpropyl, fluorophenylethyl, chlorophenylethyl,
`thienylmethyl, thienylethyl, and thienylpropyl. Examples of alkylaryl include, but are
`not limited to, toluyl, ethylphenyl, and propylpheny]l.
`The term "halogen"shall include iodine, bromine, chlorine and
`
`fluorine.
`
`The term "oxy" means an oxygen (O) atom. The term "thio" means a
`sulfur (S) atom. The term "oxo" means =O. The term “oximino” means the
`=C(H)NOHgroup.
`The term “side chain” refers to the portion of an amino acid that is
`bondedto the tetrahedral alpha carbon that is not the amino or carboxyl group.
`Nonlimiting examples of side chains include -CH2CH2CH2CH2NH3 (lysine) and —
`CHz3(alanine).
`
`The term “naturally occurring amino acids” refers to the aminoacids
`that include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic
`acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline,
`serine, threonine, tryptophan, tyrosine and valine.
`The term “unnaturally occurring amino acids” refers to amino acids
`that have alpha side chains other than those found in the natural amino

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket